About 25% of primary human breast cancers are due to the deregulated expression of ErbB2/HER2. HER2-targeted therapies have improved patient survival, but both de novo and acquired resistance remain a challenge, as only 25% of treated patients respond to the current therapies. Equivocal HER2 status also remains an issue as it affects subsequent clinical management. Following the analysis of the expression level of more than 800 miRNA in several human breast cancer cells and patient biopsies with various HER2+ status, the team has identified novel miRNA biomarkers for the diagnosis and prognosis of HER2+ cancers. This allows for further stratification of patients and offers new therapeutic strategies based on the modulation of miR-200b, -429 or -29c-3p. The team has the expertise and know-how required to measure miRNA and HER2 expression levels in biological samples as well as to assess HER2 activation status, downstream signaling and functional effects on cell proliferation and survival in breast cancer.
Keywords: ERBB2, HER2+ breast cancers, Patients stratification, MiRNA Diagnostic/prognostic, Biomarkers Equivocal HER2 status